U.S. Respiratory Syncytial Virus Vaccines Market
2022
According
to recent industry analysis on the U.S. respiratory syncytial virus
vaccines market by Persistence Market Research, a leading market research
company, the industry is projected to be valued at US$ 320.3 Mn in 2022, and is
set to expand at a CAGR of 18.2% over the next ten years. Demand for RSV
vaccines in the U.S. is expected to increase manifold due to a large numbers of
ongoing clinical trials and a strong product pipeline displaying promising
results.
During
the past 10 years, considerable progress has been made in RSV vaccine
development. Key manufacturers of these vaccines are using monoclonal
antibodies to cause passive immunization in infants. At present, there are
around 17 new RSV vaccines under clinical development, which include live attenuated,
vector-based, particle-based, and subunit vaccines.
Get
Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/33045
Presently,
key market players such as GSK, Janssen, Moderna, and Pfizer have global phase
III trials underway for RSV vaccines, which reflects a great opportunity for
industrial growth along with the launch of these products into the market in
the future. Increasing funding from government bodies plays a vital role in
driving demand for the market by supporting R&D activities in the country.
Thus,
active participation of key players in clinical trials and financial help from
the government will contribute in driving the respiratory syncytial virus
vaccines market in the U.S. to reach a valuation of US$ 1.7 Bn by the end of
2032.
For the
entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/market-research/us-respiratory-syncytial-virus-vaccines-market/toc
Key
Takeaways from Market Study
- By drug, Nirsevimab
(MEDI8897) is projected to dominate the U.S. market with US$ 406.6 Mn
valuation by 2032.
- Based on distribution
channel, institutional sales are expected to dominate the market with
revenue worth US$ 754.3 Mn by 2032.
“Increasing
number of products in clinical pipeline is anticipated to drive the U.S. market
for respiratory syncytial virus vaccines,” says a Persistence Market
Research analyst.
Market
Competition
Key
manufacturers of respiratory syncytial virus (RSV) vaccines are focusing on
inorganic growth by undergoing clinical trials on RSV vaccines for expansion of
their market share and presence, along with strengthening their capabilities
with broader offerings to meet growing market demand.
This
approach helps in the development of cost-effective vaccines with higher
efficacy and performance, which is expected to drive market growth during the
forecast period (2022 to 2032).
- In February 2022,
GlaxoSmithKline plc announced a voluntary pause in the trial enrolment and
vaccination evaluating a potential RSV maternal vaccine candidate in
pregnant women.
Access
Full Report@ https://www.persistencemarketresearch.com/checkout/33045
What Does
the Report Cover?
Persistence
Market Research offers a unique perspective and actionable insights on the U.S.
respiratory syncytial virus vaccines market in its latest study, presenting
historical demand assessment of 2017 – 2021 and projections for 2022 – 2032.
The
research study is based on the drug (Palivizumab, RSVpreF PF06928316, RSVPreF3
OA (GSK3844766A), mRNA-1345, mRNA-1345, Janssen RSV Vaccine, ResVax, Nirsevimab
(MEDI8897), and MVA-BN RSV) and distribution channel (institutional sales,
retail sales, and online sales), in the U.S.
About us: Persistence Market Research
Contact
us:
Persistence
Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
No comments:
Post a Comment